Immatics N.V. (IMTX)

NASDAQ: IMTX · IEX Real-Time Price · USD
12.56
+0.21 (1.70%)
Feb 27, 2024, 10:46 AM EST - Market open
1.70%
Market Cap 1.27B
Revenue (ttm) 75.72M
Net Income (ttm) -84.08M
Shares Out 102.97M
EPS (ttm) -1.13
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 105,224
Open 12.47
Previous Close 12.35
Day's Range 12.46 - 12.72
52-Week Range 5.90 - 13.14
Beta 0.67
Analysts Strong Buy
Price Target 18.50 (+47.29%)
Earnings Date Mar 19, 2024

About IMTX

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in ... [Read more]

Industry Biotechnology
Sector Healthcare
CEO Dr. Harpreet Singh Ph.D.
Employees 293
Stock Exchange NASDAQ
Ticker Symbol IMTX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 3 analysts, the average rating for IMTX stock is "Strong Buy." The 12-month stock price forecast is $18.5, which is an increase of 47.29% from the latest price.

Price Target
$18.5
(47.29% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Immatics Announces Pricing of $175 Million Public Offering

Houston, Texas and Tuebingen, Germany, January 17, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirec...

5 weeks ago - GlobeNewsWire

Immatics Announces Proposed Public Offering

Houston, Texas and Tuebingen, Germany, January 17, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirec...

5 weeks ago - GlobeNewsWire

Immatics Announces Third Quarter 2023 Financial Results and Business Update

Tuebingen, Germany and Houston, TX, November 14, 2023 – Immatics N.V. (NASDAQ: IMTX; “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecti...

3 months ago - GlobeNewsWire

Immatics Reports Interim Clinical Data from ACTengine® IMA203 and IMA203CD8 TCR-T Monotherapies Targeting PRAME in an Ongoing Phase 1 Trial

Company to host conference call and webcast today, November 8, at 8:30 am EST/2:30 pm CET

3 months ago - GlobeNewsWire

Immatics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ACTengine® IMA203 TCR-T Monotherapy

RMAT designation granted by FDA CBER for IMA203 cell therapy in multiple PRAME-expressing tumors including cutaneous and uveal melanoma, ovarian cancer and other cancer types Regulatory activities und...

4 months ago - GlobeNewsWire

Protalix BioTherapeutics Appoints Eliot Richard Forster, Ph.D. as Chairman of its Board of Directors

Appointment effective as of September  14, 2023; Zeev Bronfeld to retire from the Board of Directors CARMIEL, Israel , Sept. 12, 2023 /PRNewswire / Protalix BioTherapeutics, Inc. (NYSE American: PLX),...

Other symbols: PLX
6 months ago - PRNewsWire

Immatics shares rise on Moderna cancer collaboration

Immatics NV shares IMTX, -2.87% gained more than 6% premarket on Monday after the company announced a collaboration with Moderna Inc. MRNA, -0.66% to research and develop new cancer therapies. The par...

Other symbols: MRNA
6 months ago - Market Watch

Moderna, Immatics to work jointly on cancer vaccines

Vaccine maker Moderna said on Monday it had struck a deal with Immatics for developing cancer vaccines and therapies and would pay the drug developer $120 million in cash and additional milestone paym...

Other symbols: MRNA
6 months ago - Reuters

Moderna and Immatics Announce Strategic Multi-Platform Collaboration to Develop Innovative Oncology Therapeutics

Cambridge, Massachusetts and Tuebingen , Germany , September 11 , 2023 – Moderna, Inc. (NASDAQ: MRNA, “Moderna”) and Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical compan...

Other symbols: MRNA
6 months ago - GlobeNewsWire

Moderna & Immatics Announce Strategic Multi-Platform Collaboration to Develop Innovative Oncology Therapeutics

Collaboration combines leading technologies to develop breakthrough, mRNA-enabled in vivo expressed TCER® molecules Companies to leverage Immatics' XPRESIDENT® target discovery platform and Moderna's ...

Other symbols: MRNA
6 months ago - Accesswire

Immatics Announces Second Quarter 2023 Financial Results and Business Update

Tuebingen, Germany and Houston , TX, August 17 , 2023 – Immatics N.V. (NASDAQ: IMTX; “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecti...

6 months ago - GlobeNewsWire

Immatics Initiates Phase 1/2 Clinical Trial to Evaluate PRAME TCR Bispecific IMA402 in Patients with Advanced Solid Tumors

Tuebingen, Germany and Houston, Texas , August 10 , 202 3 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redir...

7 months ago - GlobeNewsWire

Immatics shares jump after investment from Bristol Myers Squibb

Shares of Immatics N.V. IMTX, +0.08% gained more than 8% premarket on Monday after the clinical-stage biopharma company said it had received a $35 million equity investment from Bristol Myers Squibb C...

Other symbols: BMY
7 months ago - Market Watch

Immatics Announces $35 Million Equity Investment from Bristol Myers Squibb

Tuebingen , Germany and Houston , TX , Ju ly 24 , 202 3 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirec...

7 months ago - GlobeNewsWire

Immatics Announces First Quarter 2023 Financial Results and Business Update

Tuebingen , Germany and Houston, TX , May 16 , 20 2 3 – Immatics N.V. (NASDAQ: IMTX; “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecti...

10 months ago - GlobeNewsWire

Immatics Reports Interim Clinical Data from Ongoing Phase 1b Cohort A Monotherapy with ACTengine® IMA203 TCR-T Targeting PRAME

Company to host conference call today, May 2, at 8:30 am EDT / 2:30 pm CEST

10 months ago - GlobeNewsWire

Immatics Announces First Bristol Myers Squibb Opt-in of TCR-T Candidate from Ongoing Multi-target Strategic Collaboration

Tuebingen, Germany & Houston, May 1, 2023 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer im...

10 months ago - GlobeNewsWire

Immatics Announces Full Year 2022 Financial Results and Corporate Update

Tuebingen , Germany and Houston, TX , March 2 1 , 20 2 3 – Immatics N.V. (NASDAQ: IMTX; “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redire...

1 year ago - GlobeNewsWire

Immatics Announces Third Quarter 2022 Financial Results and Business Update

Tuebingen , Germany and Houston, Texas , November 1 7 , 2022 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-re...

1 year ago - GlobeNewsWire

Immatics Announces $110 Million Underwritten Offering of Ordinary Shares

H ouston, Texas and Tuebingen , Germany , October 10, 2022 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redi...

1 year ago - GlobeNewsWire

Immatics Reports Interim Clinical Data Update on ACTengine® IMA203 TCR-T Monotherapy Targeting PRAME

Company to host conf e rence call today, October 10 , at 8:30 am E D T / 2:30 pm CEST

1 year ago - GlobeNewsWire

Immatics Presents Comprehensive Preclinical Data Set for TCR Bispecific Candidate IMA402 Targeting PRAME at European Society for Medical Oncology (ESMO) Congress 2022

TCER® IMA402 is a next-generation, half-life extended TCR Bispecific targeting an HLA-A*02:01-presented peptide derived from PRAME. In preclinical studies, IMA402 demonstrated enhanced anti-tumor acti...

1 year ago - GlobeNewsWire

Immatics Announces First Cancer Patient Treated with Second-Generation ACTengine® TCR-T Candidate IMA203CD8 Targeting PRAME

H ouston, Texas and Tuebingen , Germany , August 23 , 2022 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redi...

1 year ago - GlobeNewsWire

Immatics Announces Second Quarter 2022 Financial Results and Business Update

Tuebingen , Germany and Houston, Texas , August 9 , 2022 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redire...

1 year ago - GlobeNewsWire

Why you should consider buying and accumulating Immatics N.V.

Immatics N.V. (NASDAQ:IMTX) is currently valued at $7.55.

1 year ago - Invezz